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Background-—Sleep apnea (SA) is associated with an increased risk of atrial ﬁbrillation (AF). We sought to determine the effect of
SA on cardiac structure in patients with AF, whether therapy for SA was associated with beneﬁcial cardiac structural remodelling,
and whether beneﬁcial cardiac structural remodelling translated into a reduced risk of recurrence of AF after pulmonary venous
isolation (PVI).
Methods and Results-—A consecutive group of 720 patients underwent a cardiac magnetic resonance study before PVI. Patients
with SA (n=142, 20%) were more likely to be male, diabetic, and hypertensive and have an increased pulmonary artery pressure,
right ventricular volume, atrial dimensions, and left ventricular mass. Treated SA was deﬁned as duration of continuous positive
airway pressure therapy of >4 hours per night. Treated SA patients (n=71, 50%) were more likely to have paroxysmal AF, a lower
blood pressure, lower ventricular mass, and smaller left atrium. During a follow-up of 42 months, AF recurred in 245 patients. The
cumulative incidence of AF recurrence was 51% in patients with SA, 30% in patients without SA, 68% in patients with untreated SA,
and 35% in patients with treated SA. In a multivariable model, the presence of SA (hazard ratio 2.79, CI 1.97 to 3.94, P<0.0001)
and untreated SA (hazard ratio 1.61, CI 1.35 to 1.92, P<0.0001) were highly associated with AF recurrence.
Conclusions-—Patients with SA have an increased blood pressure, pulmonary artery pressure, right ventricular volume, left atrial
size, and left ventricular mass. Therapy with continuous positive airway pressure is associated with lower blood pressure, atrial
size, and ventricular mass, and a lower risk of AF recurrence after PVI. (J Am Heart Assoc. 2013;2:e000421 doi: 10.1161/JAHA.
113.000421)
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T
here are strong epidemiological data linking sleep apnea
(SA) and atrial ﬁbrillation (AF).
1,2 SA is a relatively
common condition with a prevalence of almost 20% among
adults in the United States, and the burden is increasing.
3,4
Adverse cardiovascular outcomes are common in patients
with SA
1 and include hypertension,
5 stroke,
1 heart failure,
6
and the occurrence of AF.
2 AF is the most common cardiac
rhythm disorder in SA,
7 and the complex interplay between AF
and SA has led to calls for further investigation.
8,9 Approx-
imately 50% of patients with AF are likely to have SA,
2 and
recurrence rates of AF are higher with either medical therapy
or electrical cardioversion in patients with SA.
10,11 Catheter
ablation offers a viable alternative in symptomatic patients
who are refractory to pharmacological therapy,
12,13 and the
use of catheter ablation is increasing.
14 Data suggest that the
presence of SA has an effect on the therapeutic success of
pulmonary vein isolation (PVI) for AF.
15–18 However, the
mechanisms through which SA increases the risk of AF are
unclear. Speciﬁcally, there are limited data testing the
interplay among SA, adverse cardiac structural remodeling,
and the risk for recurrence of AF. Furthermore, there are
limited data testing whether therapy for SA is associated with
a beneﬁcial effect on cardiac structural remodeling among
patients with AF. We hypothesized that SA would be
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ORIGINAL RESEARCHassociated with adverse cardiac structural remodeling, that
therapy for SA would be associated with a beneﬁcial effect on
cardiac structure, and that the treatment of SA would reduce
the incidence of AF recurrence after PVI.
Methods
We prospectively collected data on all consecutive patients
from September 2005 through June 2011 who underwent a
cardiac magnetic resonance (CMR) study before PVI at a
single institution (Brigham and Women’s Hospital). The study
indication was speciﬁcally for identiﬁcation of pulmonary vein
anatomy before planned PVI for treatment of recurrent AF.
Our institutional practice is for all patients with AF, without
standard contraindications to the performance of a magnetic
resonance study, to undergo a CMR study before PVI to
identify pulmonary vein anatomy.
19 Contraindications to a
contrast CMR study include the presence of a permanent
pacemaker, any metallic hazards, severe claustrophobia, and
severe impairment of renal function (glomerular ﬁltration rate
<30 mL/min per 1.73 m
2). Separation into paroxysmal and
persistent AF was deﬁned as consistent with guidelines.
20
Heart failure was deﬁned as a clinical history of heart failure
or reduced ejection fraction (EF). Participants were deﬁned as
having a prior myocardial infarction when a history of
myocardial infarction was supported by hospital records or
when there was evidence by ECG criteria (Minnesota codes
1.1.1 to 1.2.8).
21 All patients undergoing a ﬁrst CMR study
before PVI were included; this included patients who had a
prior failed PVI at another institution or if they did not undergo
a CMR study before the previous procedure. The presence or
absence of SA was prospectively determined before PVI with
the use of a standardized questionnaire administered to all
patients. All patients diagnosed with SA had undergone formal
sleep studies. The diagnosis of SA was established in
accordance with the sleep study criteria recommended by
the American Academy of Sleep Medicine.
22 Data regarding
the extent of use of continuous positive airway pressure
(CPAP) were obtained from each patient from follow-up phone
interviews. The protocol was approved by the Human Subjects
Research Review Committee.
CMR Protocol
All images were acquired with ECG gating, breath-holding, and
thepatientinasupineposition.Subjectswereimagedoneither
a1.5-or3.0-TCMRsystem(SignaCV/IHDXtplatform,General
Electric Healthcare, and Tim Trio, Siemens, respectively). The
CMR protocol consisted of cine steady-state free precession
imaging for cardiac function and late gadolinium enhancement
(LGE) imaging as previously described.
23 A single bolus of 0.15
mmol/kg gadolinium-diethylenetriamine pentacetate was
used.LGEwasquantiﬁedbyasemiautomaticdetectionmethod
using a previously validated method (Mass Research, Leiden
UniversityMedicalCenter).Themassofleftventricular(LV)LGE
is measured in grams, which is then expressed as a percentage
of total LV mass. LGE was quantiﬁed using regions deﬁned as
>50% of maximal signal intensity of the enhanced area
(full-width at half-maximum).
24 The distribution of LGE was
characterized as subendocardial, transmural, mid-wall, epicar-
dial, or focal/involving the insertion points.
PVI Protocol
For patients with paroxysmal AF, PVI consisted of point-by-
point radiofrequency ablation to encircle the left and right
pulmonary veins or by the use of a cryo-ballon catheter (Artic
Front, Medtronic Inc). In all cases, PVI was conﬁrmed by
recording within the veins using a circular multipolar catheter
to conﬁrm entrance block into the veins. For patients with
persistent AF, additional linear left atrial (LA) ablations were
performed in addition to PVI. Often, this consisted of linear
ablations to create conduction block across the LA roof, and
along the region between the lateral mitral annulus and left
inferior pulmonary vein.
25 Areas of complex fractionated
electrograms during AF were also targeted for ablation. If
sinus rhythm could not be restored with ablation alone,
administration of ibutilide or external cardioversion was
performed to restore sinus rhythm.
Methods of Clinical Follow-up
The outcome of interest was recurrence of AF, which was
deﬁned as AF occurring >3 months after PVI and conﬁrmed
by either ECG or prolonged cardiac monitoring. Patients
underwent ECG testing at all clinical visits; routine prolonged
cardiac monitoring was performed in the patients reporting
symptom consistent with AF. Patients were followed post
procedure monthly for the ﬁrst 3 months and then at 3- to
6-month intervals for the ﬁrst 2 years, all via clinic visits. The
duration of follow-up was determined from the CMR study
date to the occurrence of an end point. If a recurrence of AF
did not occur, patients were censored at the date of last
clinical follow-up.
Statistical Analysis
Continuous data are presented as meanSD. Continuous data
were compared using an unpaired Student t test or Mann–
Whitney nonparametric test as appropriate. Nominal data are
presented as number and percentages and were compared
with a v
2 test. The hazard ratio for the prediction of AF was
calculated using a Cox regression model. The Cox regression
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Hmodel consisted of the following clinical variables (age, sex, a
history of diabetes, heart failure, and hypertension, LA size,
body mass index, LVEF, and the use of a statin or angiotensin-
converting enzyme inhibitor) and a variable that indicated
status of SA treatment. To conﬁrm that the proportional
hazards assumption was met, we tested the proportional
hazards assumption of the relationship between SA and
recurrent AF over time by creating an interaction term in our
modelfortime.Theeffectestimatefortheinteractiontermwas
not statistically signiﬁcant (P=0.14). Patients with SA were
separatedinto2groupsbasedonthemediantimeoftreatment
withCPAP.NontreatedSAwasdeﬁnedasCPAPdurationofless
than this median duration of therapy of 4 hours. Event curves
were determined according to the Kaplan–Meier method, and
comparisons of cumulative event rates were performed by
using the log-rank test. A 2-tailed P value of <0.05 was
considered signiﬁcant for all other analyses. SAS was used for
statistical analysis (SAS Institute Inc).
Results
Study Cohort Characteristics
In total, 720 consecutive patients were referred for a CMR in
preparation for PVI. Cohort characteristics for the entire
cohort and separated according to the presence or absence of
SA are presented in Table 1. In brief, in the entire cohort, there
were 531 men (74%) with an average age of 5611 years
(range 24 to 85 years). Patients presented a median of
49 months after the ﬁrst symptomatic onset of AF (range
12 months to 12 years); 472 (65%) patients had persistent AF,
250 (35%) had paroxysmal AF, and 459 (65%) patients were in
sinus rhythm at the time of the study. Of the total cohort, 142
(20%) were identiﬁed as having SA. Other comorbidities
included diabetes in 106 (15%) patients and heart failure in
186 (26%). In total, 497 patients (69%) were receiving a class 1
or class 3 antiarrhythmic. SA was diagnosed a median of
26 months (IQR 18 to 31 months) before the CMR study, and
median CPAP use per night was 4 hours (range 0 to 8 hours).
Nonimaging variables were separated according to the pres-
ence or absence of SA (Table 1). Patients with SA were more
likely male and to have a history of hypertension and diabetes
mellitus. Patients with SA were more likely to be receiving an
angiotensin-converting enzyme inhibitor or an angiotensin II
receptor blocker and a diuretic.
Baseline Imaging Characteristics Separated
According to the Presence of SA
Imaging characteristics are presented in Table 2. On echocar-
diogram, the mean LVEF was 5510 and estimated pulmonary
artery systolic pressure was 298 mm Hg among the entire
cohort (Table 2). On CMR, the mean LV end-diastolic volume
was 16742 mL, EF was 5610%, LV mass indexed to body
surface area was 7112 g, right ventricular (RV) end-diastolic
volume was 16342 mL, and RVEF was 528% (Table 2).
Late gadolinium enhancement was present in 108 patients
(15%, Table 2). The LGE pattern was mid-myocardial in 34
(31%), subendocardial in 48 (44%), insertion point in 12 (11%)
patients, epicardial in 1 (1%), and transmural in 15 (13%). The
average extent of LGE was 6.44%. Imaging characteristics of
patients were grouped according to the presence or absence
of SA (Table 2). Patients with SA had an increased indexed LV
mass, higher estimated pulmonary artery systolic pressure,
larger LA size, and reduced RVEF compared with patients
without SA. Patients with SA had an increased incidence of
LGE compared with patients without SA. Patients with SA were
more likely to have insertion-point LGE than were patients
without SA; otherwise, there was no difference in the location
or extent of LGE between patients with and without SA.
Imaging Characteristics Separated According
to Therapy of SA
Patients with SA were further divided according to the median
CPAP treatment of 4 hours per night (Tables 3 and 4). There
were differences in patients’ characteristics and imaging
variables between SA patients above and below the median
duration of CPAP therapy. Patients who received less CPAP
therapy were more likely to have persistent than paroxysmal
AF and had a higher systolic blood pressure, an increased LV
mass, larger LA dimensions, and a lower incidence of
subendocardial LGE.
Recurrence of AF
Complete clinical follow-up was available for 715 patients
(99%). There were 245 episodes of late recurrent AF during a
median follow-up time of 42 months (IQR 23 to 50 months).
The time to recurrence of late AF ranged from 5 to
57 months. Early recurrence of AF (<3 months) was found
in 256 patients (36%). The cumulative incidence of late AF
recurrence (>3 month) was higher among patients with an
early recurrence of AF (104/256 patients, 41%) than among
patients without an early recurrence of AF (141/464 patients,
30%, P=0.006). In a clinical multivariable model, where SA
was divided into treated (>4 hours) versus untreated
(<4 hours),
26 the median duration of CPAP therapy in this
study, untreated SA provided the strongest association with
late AF recurrence (Table 5). Among all patients with SA, the
cumulative incidence of late AF recurrence was 51% com-
pared with an incidence of 30% in patients without SA.
Patients below the median CPAP therapy duration of 4 hours
had an increased rate of recurrence of late AF compared with
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Variable Entire Cohort (720) SA Positive (142) SA Negative (578) P Value
Age, y 56 (11) 57 (10) 56 (11) 0.57
Male, n (%) 531 (74) 115 (81) 416 (72) 0.03
Duration of AF, median (IQR) 49 (29 to 82) 50 (27 to 80) 50 (29 to 84) 0.86
Paroxysmal atrial fibrillation,
n (%)
249 (35) 51 (36) 198 (34) 0.77
Persistent atrial fibrillation,
n (%)
471 (65) 91 (64) 380 (66) 0.69
Prior AF ablation, n (%) 173 (24) 30 (21) 143 (25) 0.38
Cardiovascular risk factors, n (%)
Diabetes 106 (15) 33 (23) 73 (13) 0.002
Hypertension 365 (51) 90 (63) 275 (48) 0.0007
Prior myocardial infarction 56 (8) 12 (8) 44 (8) 1.00
Heart failure 186 (26) 42 (30) 144 (25) 0.29
Sleep apnea 142 (20) 142 (100) 0 (0) —
Valvular heart disease 77 (11) 6 (4) 71 (12) 0.004
Hyperthyroidism 34 (5) 5 (4) 29 (5) 0.66
Hypercholesterolemia 240 (33) 50 (35) 190 (33) 0.62
Alcohol excess 59 (8) 14 (10) 45 (8) 0.65
Family history AF 88 (12) 12 (8) 76 (13) 0.15
Medication, n (%)
Aspirin 325 (45) 67 (47) 258 (45) 0.64
b-Blocker 491 (68) 98 (69) 393 (68) 0.84
Calcium channel blocker 164 (23) 39 (27) 125 (22) 0.15
ACE/ARB 261 (36) 64 (45) 197 (34) 0.02
Class 1 antiarrhythmic 162 (23) 25 (18) 137 (34) 0.14
Class 3 antiarrhythmic 335 (47) 77 (54) 258 (45) 0.05
Digoxin 64 (9) 14 (10) 50 (9) 0.39
Spironolactone 19 (3) 4 (3) 15 (3) 0.78
Diuretics 126 (18) 35 (25) 91 (16) 0.02
Statin 222 (31) 44 (31) 178 (31) 0.61
BMI, kg/m
2 29.5 (5) 32.5 (6) 29 (5) <0.0001
Systolic blood pressure, mm Hg 127 (17) 127 (19) 127 (17) 0.81
Diastolic blood pressure, mm Hg 75 (12) 77 (11) 75 (12) 0.06
Heart rate, beats/min 73 (17) 73 (17) 72 (17) 0.77
ECG parameters
Sinus rhythm at presentation 459 (65) 85 (60) 374 (65) 0.29
AV delay, ms 172 (31) 177 (32) 171 (31) 0.18
QRS duration, ms 96 (15) 96 (13) 96 (16) 0.77
QTc duration, ms 442 (33) 442 (31) 441 (33) 0.61
LVH by ECG (Sokolov criteria) 56 (8) 16 (11) 40 (7) 0.11
GFR, mL/min per 1.73 m
2 83 (17) 83 (16) 83 (17) 0.77
All data are number (percentage) or mean (SD) unless otherwise indicated. ACE/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; AF, atrial
ﬁbrillation; AV, atrioventricular; BMI, body mass index; GFR, glomerular ﬁltration rate using the Modiﬁcation of Diet in Renal Disease formula done at the time of the CMR; LVH, left
ventricular hypertrophy; SA, sleep apnea.
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35%). Kaplan–Meier curves showing differences in late AF
recurrence according to the presence or absence of SA and
according the median CPAP treatment are presented (Figure).
There was a signiﬁcant difference in incidence of late AF
between patients without SA and patients with SA who were
not treated. There was no difference in the cumulative
incidence of AF recurrence between patients with treated SA
and those without SA.
Discussion
In patients with recurrent AF requiring PVI, we aimed to test
the effect of SA on cardiac remodeling, to test whether
therapy for SA was associated with differences in cardiac
structure, and to test whether therapy for SA affected the
recurrence rate of AF after PVI. We found that patients with
SA had increased LV mass, LA size, estimated pulmonary
pressures, and RV size, as well as reduced RV function. We
found that therapy for SA was associated with paroxysmal
rather than persistent AF, a lower blood pressure, a lower LV
mass, and a reduced LA size. Finally, we found that untreated
SA increased the incidence of AF recurrence post PVI and that
treatment of SA with CPAP is associated with a lower
incidence of AF after a successful PVI.
There are limited data comparing the CMR ﬁndings in
patients with and without SA. We found that patients with SA
were more likely to have an increased LV mass, a larger LA,
Table 2. Imaging Characteristics Stratiﬁed by SA
Variable Total Cohort (750) SA Positive (142) SA Negative (578) P Value
Echocardiographic parameters
LVEF, % 55 (10) 56 (9) 55 (11) 0.38
LV diastolic dimension, mm 49 (5) 50 (5) 49 (5) 0.09
Estimated PASP, mm Hg 29 (8) 31 (7) 28 (8) 0.0002
Left atrial dimension, mm 41 (6) 43 (6) 41 (6) 0.004
Cardiac magnetic resonance
LVEDV, mL 167 (42) 174 (43) 165 (42) 0.05
LVEDV index, mL/m
2 80 (19) 80 (20) 80 (19) 0.90
LVESV, mL 74 (28) 77 (26) 74 (28) 0.19
LVESV index, mL/m
2 36 (13) 36 (12) 36 (13) 0.89
LVEF, % 56 (10) 56 (10) 56 (10) 0.99
LV mass, g 148 (34) 164 (34) 144 (31) 0.006
LV mass index, g/m
2 71 (12) 75 (14) 70 (12) 0.001
RVEDV, mL 163 (42) 171 (44) 161 (41) 0.01
RVEDV index, mL/m
2 78 (18) 78 (19) 78 (18) 0.66
RVESV, mL 80 (26) 87 (27) 78 (26) 0.0009
RVESV index, mL/m
2 39 (12) 40 (11) 38 (12) 0.19
RVEF, % 52 (8) 51 (8) 53 (8) 0.03
Left atrial dimension, mm 41 (7) 44 (8) 40 (7) <0.0001
LV LGE, n (%) 108 (15) 30 (21) 78 (13) 0.03
LV LGE FWHM, % of LV mass 6.4 (4) 6.6 (3) 6.3 (4) 0.50
LV LGE location
Subendocardial 48 (44) 12 (44) 36 (44) 0.63
Transmural 15 (13) 3 (11) 12 (15) 0.76
Epicardial 1 (1) 0 (0) 1 (1) 0.20
Mid-myocardial 34 (31) 7 (26) 27 (33) 0.63
Insertion points 12 (11) 8 (6) 4 (1) 0.0005
All data are number (percentage) or mean (SD) unless otherwise indicated. LGE FWHM indicates late gadolinium enhancement using full-width half-maximum method; LV, left ventricular;
LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; PASP, pulmonary artery systolic pressure; RVEDV, right
ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVEF, right ventricular ejection fraction; SA, sleep apnea.
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Hand a lower RVEF. These ﬁndings are complementary to
echocardiographic data. Arias and colleagues compared LV
mass in patients with SA with healthy controls.
27 They found
that patients with SA had thicker LV walls and a higher LV
mass than controls. Otto and colleagues tested the effect of
SA on LA size in patients with SA and found that LA size was
Table 3. Characteristics of Participants With SA and Stratiﬁed by Treatment Group
Variable Total SA Cohort (142) SA Treated Group (71) SA Untreated Group (71) P Value
Age, y 57 (10) 56 (9) 57 (10) 0.60
Male, n (%) 115 (81) 60 (85) 55 (77) 0.39
Duration of AF, median (IQR) 50 (27 to 80) 49 (35 to 84) 52 (28 to 73) 0.75
Paroxysmal atrial fibrillation, n (%) 51 (36) 32 (45) 19 (27) 0.04
Persistent atrial fibrillation, n (%) 91 (64) 39 (55) 52 (73) 0.04
Prior AF ablation, n (%) 30 (21) 11 (15) 19 (27) 0.15
Cardiovascular risk factors, n (%)
Diabetes 33 (23) 16 (23) 17 (24) 1.00
Hypertension 90 (63) 47 (66) 43 (61) 0.61
Prior myocardial infarction 12 (8) 6 (8) 6 (8) 1.00
Heart failure 42 (30) 18 (25) 24 (34) 0.36
Valvular heart disease 6 (4) 2 (3) 4 (6) 0.68
Hyperthyroidism 5 (4) 3 (4) 2 (3) 1.00
Hypercholesterolemia 50 (35) 25 (35) 25 (35) 1.00
Alcohol excess 14 (10) 9 (13) 5 (7) 0.40
Family history AF 12 (8) 6 (8) 6 (8) 1.00
Medication, n (%)
Aspirin 67 (47) 37 (53) 30 (49) 0.31
b-Blocker 98 (69) 48 (68) 50 (70) 0.86
Calcium channel blocker 39 (27) 20 (28) 19 (27) 1.00
ACE/ARB 64 (45) 29 (41) 35 (49) 0.40
Class 1 antiarrhythmic 25 (18) 14 (20) 11 (15) 0.66
Class 3 antiarrhythmic 77 (54) 36 (51) 41 (58) 0.51
Digoxin 14 (10) 7 (10) 7 (10) 1.00
Spironolactone 4 (3) 2 (3) 2 (3) 1.00
Diuretics 35 (25) 13 (18) 22 (31) 0.12
Statin 44 (31) 21 (30) 23 (32) 0.86
BMI, kg/m
2 32.5 (6) 32.3 (6) 32.7 (5) 0.62
Systolic blood pressure, mm Hg 127 (19) 124 (17) 131 (18) 0.03
Diastolic blood pressure, mm Hg 77 (11) 77 (11) 76 (9) 0.23
Heart rate, beats/min 73 (17) 72 (17) 74 (18) 0.66
ECG parameters
Sinus rhythm at presentation 85 (60) 44 (62) 41 (58) 0.73
AV delay, ms 177 (32) 174 (33) 180 (31) 0.39
QRS duration, ms 96 (13) 96 (12) 97 (15) 0.85
QTc duration, ms 442 (31) 440 (30) 445 (32) 0.42
LVH by ECG (Sokolov criteria) 16 (11) 6 (8) 10 (14) 0.43
GFR, mL/min per 1.73 m
2 83 (16) 81 (16) 85 (17) 0.13
All data are number (percentage) or mean (SD) unless otherwise indicated. ACE/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; AF, atrial ﬁbrillation;
BMI, body mass index; GFR, glomerular ﬁltration rate using the Modiﬁcation of Diet in Renal Disease formula done at the time of the CMR; LVH, left ventricular hypertrophy; SA, sleep apnea.
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28 Finally, Shivalkar and
colleagues found an increased RV size by echocardiography
in patients with SA compared with healthy controls.
29
However, patients with SA tend to be overweight and have
limited echocardiographic windows. Furthermore, even among
nonoverweight subjects, CMR is the gold standard measure of
cardiac structure and function.
30,31 We also tested the effect
of treatment of SA on CMR measures of cardiac structure and
function. We found that patients receiving therapy for SA had
a lower LV mass and smaller LA. These ﬁndings are
complementary to prior published data.
32 Colish and col-
leagues tested the effect of CPAP on LV mass and LA size on
baseline and follow-up CMR-based measurement of LV mass
and LA size. Similar to the ﬁndings of the present study, they
found that therapy with CPAP was associated with a reduction
in LV mass and LA size. We extend these ﬁndings and show
that patients with treated SA had a lower LV mass, a reduced
LA size, and a reduction in the recurrence of AF.
We also compared the prevalence and pattern of myocar-
dial scar among patients with and without SA. Compared with
patients without SA, patients with SA were more likely to have
LGE. Also, the location of LGE was different between groups
with and without SA. Patients with SA were more likely to
have LGE involving the insertion points of the septal
attachments of the RV. Insertion point LGE is a nonspeciﬁc
CMR ﬁnding, occurring in dilated cardiomyopathy,
33 hyper-
trophic cardiomyopathy,
34 systemic hypertension,
35 and
pulmonary hypertension.
36 In patients with pulmonary hyper-
Table 4. Imaging Characteristics of Participants With SA and Startiﬁed by Treatment Group
Variable SA Positive (142) SA Treated (71) SA Untreated (71) P Value
Echocardiographic parameters
LVEF, % 56 (9) 56 (9) 55 (10) 0.27
LV diastolic dimension, mm 50 (5) 50 (5) 49 (6) 0.62
Estimated PASP, mm Hg 31 (7) 30 (7) 32 (8) 0.31
Left atrial dimension, mm 43 (6) 41 (6) 44 (6) 0.002
Cardiac magnetic resonance
LVEDV, mL 174 (43) 169 (40) 179 (45) 0.18
LVEDV index, mL/m
2 80 (20) 78 (19) 82 (22) 0.30
LVESV, mL 77 (26) 77 (25) 77 (25) 0.88
LVESV index, mL/m
2 36 (12) 36 (12) 35 (12) 0.74
LVEF, % 56 (10) 55 (10) 57 (10) 0.88
LV mass, g 164 (34) 154 (29) 174 (36) 0.005
LV mass index, g/m
2 75 (14) 71 (11) 80 (14) 0.0002
RVEDV, mL 171 (44) 167 (37) 176 (51) 0.27
RVEDV index, mL/m
2 78 (19) 77 (16) 80 (21) 0.47
RVESV, mL 87 (27) 86 (24) 86 (29) 0.97
RVESV index, mL/m
2 40 (11) 40 (11) 39 (12) 0.67
RVEF, % 51 (8) 50 (7) 51 (8) 0.24
Left atrial dimension, mm 44 (8) 41 (8) 46 (8) 0.0008
LV LGE, n (%) 27 (19) 12 (18) 15 (20) 0.67
LV LGE FWHM, % of LV mass 6.0 (3) 5.4 (3) 6.6 (3) 0.29
LV LGE location
Subendocardial 12 (8) 2 (3) 10 (14) 0.03
Transmural 3 (2) 2 (3) 1 (1) 1.00
Epicardial 0 (0) —— —
Mid-myocardial 7 (5) 6 (8) 3 (4) 0.49
Insertion points 8 (6) 3 (4) 5 (7) 0.72
All data are number (percentage) or mean (SD) unless otherwise indicated. LGE FWHM indicates late gadolinium enhancement using full-width half-maximum method; LV, left ventricular;
LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; PASP, pulmonary artery systolic pressure; RVEDV, right
ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVEF, right ventricular ejection fraction; SA, sleep apnea.
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36 The ﬁnding of a higher percentage of insertion-point
LGE in patients with SA in this study is likely due to higher
pulmonary artery pressure. We also separated patients with
SA into duration of treatment. Patients with treated SA were
less likely to have sub-endocardial LGE, a distribution typical
of that found after myocardial infarction. We hypothesized
that the reduction in an infarct pattern of LGE among patients
with treated with SA was related to either a reduction in AF
and the associated risk of thrombosis or a direct effect of SA
therapy on the risk of myocardial infarction.
37,38
The data conﬁrming an association between SA and AF
complement prior data.
2,6,9,11,18 Gami and colleagues tested
the association between SA and AF among a cohort of
patients referred for cardioversion of AF.
2 A diagnosis of SA
was suggested using the Berlin questionnaire in almost 50%
of patients. In that study, similar to ﬁndings noted in the
present work, the association between AF and SA was greater
than the association with traditional risk factors such as body
mass index and hypertension. In an extension of prior work,
the same group tested whether there was an association
between self-reported treatment of SA and recurrence of AF
after electrical cardioversion.
11 In a study of 37 patients with
SA, the authors found that the recurrence rate in the 12
patients with treated SA was half that of patients without SA
treatment. In patients being referred for PVI, data have shown
an association between SA and the presence of AF and an
association between SA and recurrence of AF.
15–17 There are
no prospective randomized data testing whether treatment of
SA reduces the risk of AF recurrence post PVI. In the largest
observational series by Patel and colleagues,
17 50% of
patients were not compliant with CPAP therapy. In that
group, the recurrence rate was higher than the rate in
patients who regularly used CPAP. In a recent study,
18 Fein
and Colleagues tested the association of SA, treatment of SA,
and recurrence of AF post PVI in 62 patients. Similar to this
study, they found that CPAP was associated with a 50%
reduction in recurrence of AF post PVI. However, important
differences exist. We found baseline differences in patients
with and without SA for which we able to account. We found
that patients with SA were more likely overweight, male,
diabetic, and hypertensive and had increased pulmonary
artery pressure, RV volume, atrial dimensions, and LV mass.
We believe that these baseline differences primarily relate to
the larger sample size of this present study. We also found
that therapy for SA was associated with differences among
patient groups. Based on published data
39 and the median
duration of CPAP therapy, 4 hours was chosen to separate
patients into 2 categories: treated SA and untreated SA.
Patients treated with CPAP were more likely to have
paroxysmal AF, a lower blood pressure, a lower ventricular
mass, and a smaller LA.
Table 5. Multivariable Cox Regression Model 2 for
Association With Recurrence of Atrial Fibrillation
Variable HR 95% CI LRv
2 P Value
Age 0.99 0.98 to 1.01 1.09 0.30
Male 0.99 0.73 to 1.33 0.05 0.94
History of
hypertension
1.10 0.82 to 1.47 0.41 0.52
History of diabetes
mellitus
1.13 0.80 to 1.59 0.45 0.50
SA treated* 1.14 0.74 to 1.76 0.34 0.56
SA untreated* 2.79 1.97 to 3.94 33.79 <0.0001
History of heart
failure
0.82 0.59 to 1.13 1.48 0.22
ACE/ARB Inhibitor 1.30 0.98 to 1.73 3.26 0.07
Statin use 0.91 0.69 to 1.22 0.38 0.53
Body mass index 0.99 0.96 to 1.02 0.84 0.36
Cardiac magnetic resonance parameters
LVEF 1.00 0.98 to 1.01 0.46 0.49
Left atrial
dimension
1.03 1.01 to 1.05 8.38 0.004
ACE/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin II receptor
blocker; HR, hazard ratio; LR, log-rank; LVEF, left ventricular ejection fraction;
SA, sleep apnea.
*Reference group=no SA.
Figure. Kaplan–Meier curves displaying probability of AF recur-
rence according to the both the presence of absence of SA, and
according to the SA treatment group. Results were compared using a
log-rank test; P value of <0.0001 for comparison of SA vs no SA and
for comparison of SA and treatment vs untreated SA group. AF
indicates atrial ﬁbrillation; SA, sleep apnea.
DOI: 10.1161/JAHA.113.000421 Journal of the American Heart Association 8
OSA, Cardiac Structure, and AF Neilan et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
HThis study should be interpreted within the context of the
design format. We did not perform serial prolonged monitoring
for the recurrence of AF. Conﬁrmation of recurrence was
performed based on patient symptoms and underestimated
the true incidence of AF recurrence. The study was prospective
but observational; therefore, the extent of monitoring was left
to the discretion of the primary providers and was not
prespeciﬁed. Due to the study design, patients were not
randomized; therefore, unanticipated variables could have
inﬂuenced the ﬁndings. We did not capture the central apnea
indices on all patients and were therefore unable to charac-
terize the patients as having central SA, obstructive SA, or
mixed patterns. We did not perform a formal sleep study on all
patients referred for PVI. This approach likely yielded a
signiﬁcant underestimation in the prevalence of SA, which is
estimated to be close to 50% in this population.
2 We also did
not randomize patients with SA to duration of CPAP therapy.
However, this study may act as a basis for such further work
where a formal sleep assessment of all patients being referred
to PVI would occur, followedby randomization to CPAP therapy
or no therapy, a testing of the effect on cardiac structure, and
the inclusion of routine prolonged monitoring for AF.
Among a large cohort of patients with recurrent AF being
referred for PVI, we found that 20% had SA, that the presence
of SA was associated with adverse cardiac remodeling, that
these adverse cardiac structural changes were attenuated
among patients treated for SA, and that the presence or
absence of therapy for SA provided a very strong association
with the incidence of AF recurrence. These data may support
further investigation into the role of therapy for SA and the
recurrence of AF after PVI.
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